Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Antibiotic resistance · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in antibiotic resistance compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 1 [0.68, 1.48]
Studies not reported
Moderate
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with bronchiectasis
2 findings from 1 review
no estimate extracted
Studies not reported
High
no estimate extracted
Studies not reported
High
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Antibiotic resistance · people with bronchiectasis
14 days on/off antibiotic regimen leads to higher antibiotic resistance compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 2.14 [1.36, 3.35]
Studies not reported
High
Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with bronchiectasis
2 findings from 1 review
no estimate extracted
Studies not reported
High
no estimate extracted
Studies not reported
Moderate
Exacerbation frequency · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in exacerbation frequency compared with 28 days on/off placebo regimen (high certainty).
2 findings from 1 review
RR 0.92 [0.82, 1.02]
Studies not reported
High
no estimate extracted
Studies not reported
Low
QoL · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Androgen normalisation · people with CAH
1 finding from 1 review
Prevention of adrenal crisis · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of osteopenia · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence of testicular or ovarian adrenal rest tumours · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Subfertility · people with CAH
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final adult height · people with CAH
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Growth and nutritional status · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
It is very uncertain whether inhaled tobramycin (TNS) (28 days) changes frequency of infective pulmonary exacerbations: number of… compared with TNS (56 days) (very low certainty).
1 finding from 1 review
Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review